Basilea Pharmaceutica Financials
| BPMUF Stock | USD 52.83 0.00 0.00% |
Basilea |
Understanding current and past Basilea Pharmaceutica Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Basilea Pharmaceutica's financial statements are interrelated, with each one affecting the others. For example, an increase in Basilea Pharmaceutica's assets may result in an increase in income on the income statement.
Basilea Pharmaceutica Stock Summary
Basilea Pharmaceutica competes with Reviva Pharmaceuticals, Protalix Biotherapeutics, Eyepoint Pharmaceuticals, Sellas Life, and ProQR Therapeutics. Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA PHARMACEUTICA is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Grenzacherstrasse 487, Basel, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.basilea.com |
| Phone | 41 61 606 11 11 |
| Currency | USD - US Dollar |
Basilea Pharmaceutica Key Financial Ratios
There are many critical financial ratios that Basilea Pharmaceutica's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Basilea Pharmaceutica reports annually and quarterly.| Return On Asset | 0.0261 | |||
| Number Of Employees | 177 | |||
| Beta | 0.88 | |||
| Z Score | -0.6 |
Basilea Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Basilea Pharmaceutica's current stock value. Our valuation model uses many indicators to compare Basilea Pharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Basilea Pharmaceutica competition to find correlations between indicators driving Basilea Pharmaceutica's intrinsic value. More Info.Basilea Pharmaceutica AG is number one stock in return on asset category among its peers. It also is number one stock in profit margin category among its peers fabricating about 0.21 of Profit Margin per Return On Asset. The ratio of Return On Asset to Profit Margin for Basilea Pharmaceutica AG is roughly 4.66 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Basilea Pharmaceutica's earnings, one of the primary drivers of an investment's value.Basilea Pharmaceutica Systematic Risk
Basilea Pharmaceutica's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Basilea Pharmaceutica volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Basilea Pharmaceutica correlated with the market. If Beta is less than 0 Basilea Pharmaceutica generally moves in the opposite direction as compared to the market. If Basilea Pharmaceutica Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Basilea Pharmaceutica is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Basilea Pharmaceutica is generally in the same direction as the market. If Beta > 1 Basilea Pharmaceutica moves generally in the same direction as, but more than the movement of the benchmark.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| CEOs Directory Screen CEOs from public companies around the world |